Dystrophin

Subscribe to Selected New Research on Dystrophin

2051 relevant articles (32 outcomes, 129 trials/studies) found for this Bio-Agent

Description: A muscle protein localized in surface membranes which is the product of the Duchenne/Becker muscular dystrophy gene. Individuals with Duchenne muscular dystrophy usually lack dystrophin completely while those with Becker muscular dystrophy have dystrophin of an altered size. It shares features with other cytoskeletal proteins such as SPECTRIN and alpha-actinin but the precise function of dystrophin is not clear. One possible role might be to preserve the integrity and alignment of the plasma membrane to the myofibrils during muscle contraction and relaxation. MW 400 kDa.

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Chamberlain, Jeffrey S: 7 articles (08/2008 - 03/2002)
2.	Duan, Dongsheng: 7 articles (02/2008 - 03/2002)
3.	Matsuo, M: 6 articles (10/2005 - 01/2000)
4.	Takeshima, Y: 5 articles (10/2005 - 01/2000)
5.	Fardeau, Michel: 5 articles (01/2005 - 10/2002)
6.	Braun, Serge: 5 articles (01/2005 - 10/2002)
7.	Yue, Yongping: 4 articles (01/2008 - 09/2003)
8.	Yagi, Mariko: 4 articles (01/2008 - 08/2004)
9.	Takeshima, Yasuhiro: 4 articles (01/2008 - 08/2004)
10.	Matsuo, Masafumi: 4 articles (01/2008 - 08/2004)

Related Diseases

1.	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 07/01/1997 - "Hopes ran high that a cure for Duchenne muscular dystrophy (DMD) would quickly follow the discovery of dystrophin by Lou Kunkel and his group in the 1980's. " 01/01/2007 - "BACKGROUND: Duchenne muscular dystrophy (DMD) is an X-linked recessive disease caused by mutations of dystrophin gene, there is no effective treatment for this disorder at present. " 03/01/2004 - "Despite a wealth of recent information about the molecular basis of Duchenne muscular dystrophy (DMD), there is no effective treatment for this condition because the mechanism how dystrophin deficiency produces the muscle fiber degradation is unknown. " 03/01/1992 - "An improved method by quantitative dystrophin gene deletion analysis was developed for the detection of Duchenne/Becker muscular dystrophy (DMD/BMD) carriers. " 08/01/1989 - "Improved diagnosis of Becker muscular dystrophy by dystrophin testing." Order ALL the reference details at left...
2.	Muscular Dystrophies (Muscular Dystrophy) 11/03/2008 - "We show that sarcospan (SSPN), a unique tetraspanin-like component of the DGC, ameliorates muscular dystrophy in dystrophin-deficient mdx mice. " 01/04/2008 - "A cure for dystrophin-deficient muscular dystrophy requires treating both skeletal muscle and the heart. " 07/01/2003 - "Expression of dystrophin driven by the 1.35-kb MCK promoter ameliorates muscular dystrophy in fast, but not in slow muscles of transgenic mdx mice." 02/01/1998 - "Elucidating the mechanisms leading to cell death may help to explain the variabilities in disease expression that are seen as a function of age, among different muscles, and across species in animals with muscular dystrophy due to dystrophin deficiency." 07/01/2005 - "Our data address important structure/function and genotype/phenotype correlations and it suggests that dystrophin protein studies must be interpreted with caution in deletion-negative male muscular dystrophy patients." Order ALL the reference details at left...
3.	Necrosis 04/01/2001 - "However, the exact functions of dystrophin are still not fully understood and the complex process leading to subsequent muscle fiber necrosis has not been clearly described; hence there has not yet been any marked improvement in patient treatment. " 04/01/2002 - "These results suggest that a combination of promoting muscle regenerative capacity and preventing muscle necrosis could be an effective treatment for the secondary symptoms caused by the primary loss of dystrophin." 04/15/2006 - "To explore the mechanisms of myofiber necrosis in dystrophin-deficient muscle, we tested the hypothesis that restoration of this complex without a link to the cytoskeleton ameliorates dystrophic pathology. " 03/01/1999 - "This study shows that limb immobilization prevents the occurrence of the first round of myofiber necrosis in mdx mice and suggests that muscle contractions play a role in the skeletal muscle degeneration of dystrophin-deficient mdx mouse muscles." 11/01/1995 - "This review discusses critically the results of these studies and their relevance to understanding the mechanisms by which dystrophin-deficiency leads to muscle necrosis." Order ALL the reference details at left...
4.	Muscular Diseases (Myopathy) 05/26/1988 - "The biochemical assay for dystrophin should prove helpful in delineating myopathies that overlap clinically with Duchenne's and Becker's dystrophies, and it shows promise as an accurate diagnostic tool." 10/01/2005 - "This study brings a new insight in the pathophysiology of dystrophin-related myopathies. " 12/13/2002 - "This study suggests that blood flow regulation might be disturbed in dystrophin-related myopathies, possibly increasing organ damage." 11/01/1995 - "A large number of recent studies have used the mdx mouse model to examine the potential role of dystrophy in normal muscle and the mechanisms by which dystrophin-deficiency leads to myopathy. " 05/01/1993 - "His unique clinical features, as well as myopathy, are reported, although further study is necessary to clarify the relationship between the anomalous conditions and dystrophin abnormalities." Order ALL the reference details at left...
5.	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 02/01/2005 - "Genomic and transcription studies as diagnostic tools for a prenatal detection of X-linked dilated cardiomyopathy due to a dystrophin gene mutation." 05/14/2004 - "In vivo study of an aberrant dystrophin exon inclusion in X-linked dilated cardiomyopathy." 09/18/2002 - "OBJECTIVES: The goal of this study was to perform comprehensive mutation analysis of the dystrophin gene in patients with X-linked dilated cardiomyopathy (XLCM). " 09/23/1998 - "Study on mutations affecting the muscle promoter/first exon of the dystrophin gene in 92 Japanese dilated cardiomyopathy patients." 05/01/1995 - "Molecular genetic studies have delineated the gene for BTHS, which maps to distal Xq28, from the gene for so called X linked dilated cardiomyopathy (XLCM), a teenage onset dilated cardiomyopathy, recently mapped to the 5' portion of the dystrophin locus at Xp21. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Glycoproteins (Glycoprotein)
2.	Utrophin
3.	Complementary DNA (cDNA)
4.	Dystroglycans (Dystroglycan)
5.	Proteins (Proteins, Gene)
6.	Protein Isoforms (Isoforms)
7.	Tubulin
8.	Insulin (Novolin)
9.	heat shock transcription factor (heat shock transcription factors)
10.	RNA Precursors (Precursor, mRNA)

Related Therapies and Procedures

1.	Intramuscular Injections
2.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
3.	Intravenous Injections
4.	Transplantation (Transplant Recipients)
5.	Lasers (Laser)

Best Treatments:
Research Summary Report
on Duchenne Muscular Dystrophy

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 55 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>